UNSPSC 51201817: Pidotimod

This classification denotes an immunostimulant with the molecular formula C9H12N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 785363R681, chemically known as 4-thiazolidinecarboxylic acid, 3-((5-oxo-2-pyrrolidinyl)carbonyl)-, (r-(r*,s*))- but generally known as pidotimod, which bears US NIH Compound Identifier 65944. European Medicines Agency schedules Pidotimod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09826MIG.

UNSPSC 51201817 Pidotimod is a Commodity code for immunological agents and vaccines, though recent state and local procurement activity under this code shows minimal relevant solicitation. The Mississippi State Department of Health posted a sole source notice on July 13, 2026 for Yellow Fever Vaccine from Sanofi Pasteur, Inc., with an objection deadline of August 3, 2026—but this procurement is for a finished vaccine product rather than pidotimod, an immunostimulant pharmaceutical agent. The notice structure reflects state-level health department procurement practice: a proposed sole source award with a formal objection period, requiring any challenger to demonstrate alternative vendor availability and file detailed supporting documentation. The solicitation does not specify quantity, contract term, estimated value, or pricing.

State and local governments show limited recent procurement activity under this Commodity code. The single recent opportunity surfaces from Mississippi's health department, a state-level health agency. Geographic concentration cannot be meaningfully characterized from a single notice. The mismatch between the code's nominal scope (pidotimod) and the actual opportunity posted (yellow fever vaccine) suggests this code may see infrequent use in state and local procurement, or that jurisdictions occasionally misclassify immunological and vaccine purchases. Firms tracking this code should monitor health department notices from state health agencies and disease control programs, where sole source and competitive vaccine and immunological-agent procurements occasionally appear, but should not expect robust or frequent activity under this specific Commodity classification.